XenoPort XP-C-069 Phase 2 Results Released
Published Thursday, March 1, 2012 4:00 am
by Jackie Cossmon

SANTA CLARA, Calif. -  XenoPort, Inc. announced today preliminary top-line results of a Phase 2, randomized, crossover clinical trial that compared optimized treatment with either Sinemet (immediate-release levodopa/carbidopa) or XP21279 co-formulated with carbidopa (279/CD) in advanced Parkinson’s disease patients with motor fluctuations. 279/CD dosed three times per day reduced mean daily “off time” by 46% compared to baseline when the patients were taking their pre-trial Sinemet dosing regimen. However, in the primary analysis of the trial, the improvement with 279/CD was not statistically better than the improvement seen with optimized Sinemet dosed four or five times per day during the double-blind phase of the trial.

 Read the full article.

Please contact our Clinical Trials team if you have any questions at clinicaltrials@thepi.org or call 408.542.5608.

Send this page to a friend

Show Other Stories

XenoPort, Inc.
675 Almanor Avenue | Sunnyvale, CA 94085
408.734.2800 main | 408.734.8455 fax (Main) | 408.734.9208 fax (Clinic Secure)